TGF-β inhibitors for the treatment of cancer

被引：64
|
作者：
Lahn, M [1 ]
Kloeker, S [1 ]
Berry, BS [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Therapeut Area Oncol, Indianapolis, IN 46285 USA
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2005年 / 14卷 / 06期
关键词：
antisense oligonucleotide; cancer; clinical Studies; knockout mice; monoclonal antibodies; TGF-beta; TGF-beta RI kinase inhibitors;
D O I：
10.1517/13543784.14.6.629
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Advances in understanding the role of transforming growth factor (TGF)-beta in tumorigenesis have led to the development of TGF-beta inhibitors for cancer treatment. Three platforms of TGF-beta inhibitors have evolved: antisense oligonucleotides, monoclonal antibodies and small molecules. in this review, the current stage of development of each known TGF-beta inhibitor will be discussed. As part of the risk/benefit assessment of TGF-beta inhibitors, the known effects of TGF-beta deficiency in mice, non-clinical toxicology studies with TGF-beta inhibitors in rats, and the clinical studies with monoclonal antibodies against TGF-beta will be summarised.
引用
收藏
页码：629 / 641
页数：13
相关论文
共 50 条
  • [31] TGF-β expression in vulvar cancer
    Karon, Przemyslaw
    Olejek, Anita
    Olszak-Wasik, Katarzyna
    GINEKOLOGIA POLSKA, 2014, 85 (11) : 847 - 851
  • [32] Stromal Modulators of TGF-β in Cancer
    Costanza, Brunella
    Umelo, Ijeoma Adaku
    Bellier, Justine
    Castronovo, Vincent
    Turtoi, Andrei
    JOURNAL OF CLINICAL MEDICINE, 2017, 6 (01)
  • [33] Targeting TGF-β Signaling in Cancer
    Colak, Selcuk
    ten Dijke, Peter
    TRENDS IN CANCER, 2017, 3 (01): : 56 - 71
  • [34] Long lasting inhibition of TGF-β receptor Type 1 inhibitor (TGF-β R1) for treatment of pancreatic cancer
    Rodriguez-Aguayo, Cristian
    Bayraktar, Emine
    Shen, Haifa
    Lopez-Berestein, Gabriel
    CANCER RESEARCH, 2017, 77
  • [35] The dynamic roles of TGF-β in cancer
    Meulmeester, Erik
    ten Dijke, Peter
    JOURNAL OF PATHOLOGY, 2011, 223 (02): : 205 - 218
  • [36] TGF-β3 and cancer: A review
    Laverty, H. G.
    Wakefield, L. M.
    Occleston, N. L.
    O'Kane, S.
    Ferguson, M. W. J.
    CYTOKINE & GROWTH FACTOR REVIEWS, 2009, 20 (04) : 305 - 317
  • [37] TGF-β in cancer and as a therapeutic target
    Pinkas, Jan
    Teicher, Beverly A.
    BIOCHEMICAL PHARMACOLOGY, 2006, 72 (05) : 523 - 529
  • [38] THE CLINICALLY USEFUL TGF-β INHIBITORS PIRFENIDONE AND LOSARTAN PARTIALLY REVERSE TGF-β-INDUCED MUCOCILIARY DYSFUNCTION
    Schmid, A.
    Baumlin, N.
    Ivonnet, P.
    Manzanares, D.
    Salathe, M.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 223 - 223
  • [39] Investigation of the Effects of TGF- β and TGF- β Inhibitors on Cell Proliferation and Senescence in Human Corneal Endothelial Cells
    Ozen, Ebru Avci
    Toprak, Emine Kilic
    Donmez, Aysegul Cort
    Toprak, Ibrahim
    ACTA PHYSIOLOGICA, 2023, 237 : 25 - 25
  • [40] Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling
    Parichatikanond, Warisara
    Luangmonkong, Theerut
    Mangmool, Supachoke
    Kurose, Hitoshi
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2020, 7
12345